The molecular landscape of breast mucoepidermoid carcinoma
Cancer Medicine · 2023
DOI: 10.1002/cam4.5754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Konstantinos Venetis und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Mucoepidermoid, Salivary Gland Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mucoepidermoid carcinoma (MEC) of the breast is an extremely rare salivary gland‐type tumor characterized by epidermoid, basaloid, intermediate, and/or mucinous cells arranged in solid and cystic patterns. Despite their triple‐negative phenotype, breast MECs are generally considered low‐risk malignancies but their biology is largely unexplored; therefore, guidelines for clinical management are lacking. Here, we sought to characterize the molecular landscape of breast MECs. Thirteen cases were histologically reviewed, characterized for tumor‐infiltrating lymphocytes (TILs), and were subjected to immunohistochemistry for programmed death‐ligand 1 (PD‐L1, clone 22C3), EGFR, and amphiregulin (AREG). Rearrangements in MAML2 and EWSR1 were investigated by fluorescent in situ hybridization. Targeted next‐generation sequencing of 161 genes was performed on eight cases. Most MECs had low histological grade ( n = 10, 77%), with the presence of TILs ( n = 9/12; 75%) and PD‐L1 combined positive score ranging from 10 to 20 ( n = 4/6; 67%). All cases showed EGFR and AREG overexpression and were fusion negative. Enrichment of genetic alterations was observed in PI3K/AKT/mTOR and cell cycle regulation pathways, while only one case harbored TP53 mutations. This is the first study providing extensive molecular data on breast MECs and the largest collection of cases available to date in the literature. Breast MECs lack TP53 mutations found in high‐grade forms of triple‐negative breast cancers and MAML2 or EWSR1 rearrangements pathognomonic of salivary MECs. Triple‐negativity and PD‐L1 positivity suggest a window of opportunity for immunotherapy in these patients. The EGFR/AREG axis activation, coupled with the mutational patterns in PI3K/AKT/mTOR and cell cycle pathways warrants caution in considering MECs as low‐risk neoplasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- Division of Anatomic Pathology, Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
- Department of Public Health, University Federico II, Naples, Italy.
- Department of Medicine and Surgery, Pathology, University Milan Bicocca, Milan, Italy.
ORCID-Profile: Chiara Rossi, Nicola Fusco
Zitieren
APA
Venetis, K., Sajjadi, E., Ivanova, M., Andaloro, S., Pessina, S., Zanetti, C., Ranghiero, A., Citelli, G., Rossi, C., Lucioni, M., Malapelle, U., Pagni, F., Barberis, M., Guerini-Rocco, E., Viale, G., & Fusco, N. (2023). The molecular landscape of breast mucoepidermoid carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.5754
Vancouver
Venetis K, Sajjadi E, Ivanova M, Andaloro S, Pessina S, Zanetti C, et al. The molecular landscape of breast mucoepidermoid carcinoma. Cancer Medicine. 2023. doi:10.1002/cam4.5754
BibTeX
@article{Venetis2023,
author = {Venetis, Konstantinos and Sajjadi, Elham and Ivanova, Mariia and Andaloro, Silvia and Pessina, Simona and Zanetti, Chiara and Ranghiero, Alberto and Citelli, Gabriele and Rossi, Chiara and Lucioni, Marco and Malapelle, Umberto and Pagni, Fabio and Barberis, Massimo and Guerini-Rocco, Elena and Viale, Giuseppe and Fusco, Nicola},
title = {The molecular landscape of breast mucoepidermoid carcinoma},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5754}
}
EUVIMED